Company / Return on Equity (ROE)
Catalyst Pharmaceuticals Partners, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
22.5%
FY2025
5-year range
18.4% / 27.7%
FY2021-FY2025
Trend
-0.3%
vs FY2024
Sector context
#20 of 190
Health Care
What the data says
Catalyst Pharmaceuticals Partners, Inc.'s return on equity (roe) of 22.5% is higher than 89% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -67.0% in FY2018 to 44.2% in FY2020.
Based on SEC 10-K filings.
22.5% in FY2025 with a 5-year CAGR of -21.8%. Top quartile in the Health Care sector.
Improved from 18.4% to 22.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -5.2pp
- 5-Year Change
- -21.8pp
- 10-Year Change
- -
Sector benchmark
+144.6% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 0.3% year-over-year.
- Currently 72.8pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 22.5% | -0.3% |
| FY2024 | 22.5% | +22.3% |
| FY2023 | 18.4% | -33.4% |
| FY2022 | 27.7% | +44.8% |
| FY2021 | 19.1% | -56.8% |
| FY2020 | 44.2% | +21.6% |
| FY2019 | 36.4% | +154.3% |
| FY2018 | -67.0% | -30.1% |
| FY2017 | -51.5% | -11.9% |
| FY2016 | -46.0% | -26.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026